734 related articles for article (PubMed ID: 19246243)
21. Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies.
Ballatore C; Brunden KR; Trojanowski JQ; Lee VM; Smith AB; Huryn DM
Curr Top Med Chem; 2011; 11(3):317-30. PubMed ID: 21320060
[TBL] [Abstract][Full Text] [Related]
22. Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer's disease and other tauopathies.
Xia Y; Prokop S; Gorion KM; Kim JD; Sorrentino ZA; Bell BM; Manaois AN; Chakrabarty P; Davies P; Giasson BI
Acta Neuropathol Commun; 2020 Jun; 8(1):88. PubMed ID: 32571418
[TBL] [Abstract][Full Text] [Related]
23. Current strategies for the treatment of Alzheimer's disease and other tauopathies.
Dickey CA; Petrucelli L
Expert Opin Ther Targets; 2006 Oct; 10(5):665-76. PubMed ID: 16981824
[TBL] [Abstract][Full Text] [Related]
24. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies.
Nakashima H; Ishihara T; Suguimoto P; Yokota O; Oshima E; Kugo A; Terada S; Hamamura T; Trojanowski JQ; Lee VM; Kuroda S
Acta Neuropathol; 2005 Dec; 110(6):547-56. PubMed ID: 16228182
[TBL] [Abstract][Full Text] [Related]
25. Tauopathies: Mechanisms and Therapeutic Strategies.
Tan CC; Zhang XY; Tan L; Yu JT
J Alzheimers Dis; 2018; 61(2):487-508. PubMed ID: 29278892
[TBL] [Abstract][Full Text] [Related]
26. Early intervention of tau pathology prevents behavioral changes in the rTg4510 mouse model of tauopathy.
Wang X; Smith K; Pearson M; Hughes A; Cosden ML; Marcus J; Hess JF; Savage MJ; Rosahl T; Smith SM; Schachter JB; Uslaner JM
PLoS One; 2018; 13(4):e0195486. PubMed ID: 29624602
[TBL] [Abstract][Full Text] [Related]
27. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies.
Brunden KR; Trojanowski JQ; Lee VM
Nat Rev Drug Discov; 2009 Oct; 8(10):783-93. PubMed ID: 19794442
[TBL] [Abstract][Full Text] [Related]
28. Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies.
Reynolds MR; Reyes JF; Fu Y; Bigio EH; Guillozet-Bongaarts AL; Berry RW; Binder LI
J Neurosci; 2006 Oct; 26(42):10636-45. PubMed ID: 17050703
[TBL] [Abstract][Full Text] [Related]
29. [The proceeding of drug development based on the propagation of tau protein].
Suzuki G; Hasegawa M
Nihon Rinsho; 2016 Mar; 74(3):432-7. PubMed ID: 27025082
[TBL] [Abstract][Full Text] [Related]
30. Alzheimer's disease: phenotypic approaches using disease models and the targeting of tau protein.
Lauretti E; Praticò D
Expert Opin Ther Targets; 2020 Apr; 24(4):319-330. PubMed ID: 32116063
[No Abstract] [Full Text] [Related]
31. Tau Hyperphosphorylation and Oxidative Stress, a Critical Vicious Circle in Neurodegenerative Tauopathies?
Alavi Naini SM; Soussi-Yanicostas N
Oxid Med Cell Longev; 2015; 2015():151979. PubMed ID: 26576216
[TBL] [Abstract][Full Text] [Related]
32. Turning down tau phosphorylation.
Fischer PM
Nat Chem Biol; 2008 Aug; 4(8):448-9. PubMed ID: 18641620
[TBL] [Abstract][Full Text] [Related]
33. Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.
Lewis J; Dickson DW
Acta Neuropathol; 2016 Jan; 131(1):27-48. PubMed ID: 26576562
[TBL] [Abstract][Full Text] [Related]
34. An Overview on the Clinical Development of Tau-Based Therapeutics.
Medina M
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29641484
[TBL] [Abstract][Full Text] [Related]
35. Tau and Axonal Transport Misregulation in Tauopathies.
Combs B; Mueller RL; Morfini G; Brady ST; Kanaan NM
Adv Exp Med Biol; 2019; 1184():81-95. PubMed ID: 32096030
[TBL] [Abstract][Full Text] [Related]
36. Altered Proteostasis in Neurodegenerative Tauopathies.
Papanikolopoulou K; Skoulakis EMC
Adv Exp Med Biol; 2020; 1233():177-194. PubMed ID: 32274757
[TBL] [Abstract][Full Text] [Related]
37. In vitro aggregation assays using hyperphosphorylated tau protein.
Sui D; Liu M; Kuo MH
J Vis Exp; 2015 Jan; (95):e51537. PubMed ID: 25590418
[TBL] [Abstract][Full Text] [Related]
38. Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules.
Rauch JN; Olson SH; Gestwicki JE
Cold Spring Harb Perspect Med; 2017 Jul; 7(7):. PubMed ID: 27940599
[TBL] [Abstract][Full Text] [Related]
39. Pathological conformations involving the amino terminus of tau occur early in Alzheimer's disease and are differentially detected by monoclonal antibodies.
Combs B; Hamel C; Kanaan NM
Neurobiol Dis; 2016 Oct; 94():18-31. PubMed ID: 27260838
[TBL] [Abstract][Full Text] [Related]
40. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies.
Ferrer I; Blanco R; Carmona M; Puig B
J Neural Transm (Vienna); 2001; 108(12):1397-415. PubMed ID: 11810404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
